Corvus Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 28
- Market Cap
- $254.5M
- Website
- http://www.corvuspharma.com
- Introduction
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR In...
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06561048
- Locations
- 🇺🇸
Corvus Clinical Trials Information, Burlingame, California, United States
Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT06345404
- Locations
- 🇺🇸
Corvus Clinical Trials Information, Burlingame, California, United States
CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients
- Conditions
- Interventions
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT04734873
- Locations
- 🇺🇸
Torrance Memorial Medical Center, Torrance, California, United States
🇵🇪Hospital Central Fuerza Aérea del Perú, Miraflores, Lima, Peru
🇵🇪Hospital María Auxiliadora, San Juan De Miraflores, Lima, Peru
Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04464395
- Locations
- 🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸El Centro Regional Medical Center, El Centro, California, United States
Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2020-02-21
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT04280328
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT03952078
- Locations
- 🇰🇷
Seoul St. Mary's Hospital, Seoul, Gyeonggido, Korea, Republic of
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇦🇺Epworth Healthcare, Melbourne, Victoria, Australia
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
- First Posted Date
- 2018-03-06
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 117
- Registration Number
- NCT03454451
- Locations
- 🇺🇸
The John Hopkins University, Baltimore, Maryland, United States
🇦🇺Lifehouse, Camperdown, New South Wales, Australia
🇺🇸NY Hematology, Albany, New York, United States
Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2018-01-26
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03237988
- Locations
- 🇺🇸
Covance Clinical Research Unit, Dallas, Texas, United States
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
- Conditions
- Interventions
- First Posted Date
- 2016-01-14
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 502
- Registration Number
- NCT02655822
- Locations
- 🇨🇦
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada